실크 단백질 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the silk protein market size is expected to grow from USD 1.24 billion in 2025 to USD 1.33 billion in 2026 and is forecast to reach USD 1.86 billion by 2031 at 7.01% CAGR over 2026-2031.

This report is Segmented by Protein Type (Fibroin, Sericin, and More), Form (Powder, Liquid, Nano-Formulation), Application (Personal Care and Cosmetics, Biomedical and Pharmaceutical, and More), End-User Industry (Textile & Apparel Companies and More), and Geography (Asia-Pacific, North America, Europe, South America, and Middle-East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

Global Silk Protein Market Trends and Insights

Growing Demand for Natural and Functional Ingredients in Cosmetics

Recognizable proteins are gaining importance as clean-beauty labels focus on proven performance in shorter testing cycles. A vegan fermentation-derived silk, launched in 2024, achieved a sevenfold reduction in visible pore area within fifteen minutes, surpassing synthetic polymers and meeting European Union (EU) claims substantiation rules. Legacy sericin, traditionally sourced from cocoons, is being reintroduced as an anti-wrinkle film former. Premium brands, priced at USD 98 per 30 milliliters, reported a replenishment rate exceeding 40% in 2026 e-commerce data. The dual approval of both topical and ingestible formats in Japan and South Korea enhances value capture, as a single extraction campaign services two profit centers. Retailers replacing banned microplastics are integrating silk peptides into existing formulation lines with minimal equipment changes, reducing conversion costs and accelerating compliance. The combination of efficacy data and sustainability narratives has expanded silk proteins from niche Asian stock-keeping units (SKUs) to mainstream Western assortments.

Surging Biomedical Use in Wound Dressings and Drug Delivery

Hospital buyers are transitioning from polypropylene meshes to silk fibroin scaffolds. These silk scaffolds demonstrate zero hypersensitivity reactions and result in savings of USD 465.91 per arthroplasty case. A Phase III trial in Japan achieved 90% wound-bed preparation within two weeks, outperforming hydrocolloids and supporting reimbursement approval. Laboratory studies showed that silver-treated silk reduced Escherichia coli counts by 95%, meeting infection-control protocols without silver-ion toxicity. The tunable degradation profiles of fibroin films enable direct delivery of antibiotics or growth factors to wounds, reducing the need for systemic dosing. Additionally, the U.S. Food and Drug Administration's (FDA) "Generally Recognized as Safe" status for edible silk coatings has initiated pre-Investigational New Drug (pre-IND) discussions for oral drug carriers, indicating potential for silk-based therapeutics.

High Extraction and Purification Costs

Purifying sericin from degumming wastewater involves energy-intensive processes such as dialysis and freeze-drying, which increase costs to USD 15-88 per kilogram, exceeding commodity pricing. Small-scale extractors face challenges in securing capital for low-temperature alkali treatments that enhance tensile strength by 50%. Evonik's automated production line in Slovakia, operational since 2025, has not disclosed unit economics, indicating the continued need for premium market positioning. Approximately 50,000 tons of sericin are discarded annually. A technological advancement in cost-effective purification methods could significantly increase supply and reduce prices. While extraction remains more cost-efficient than fermentation, which has yet to surpass the 1,112 milligrams per liter (mg/L) benchmark, scaling extraction outside Asia is constrained by the lack of comparable labor cost advantages.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Interest in Sustainable and Biodegradable Textiles
2. Regulatory Push for Microplastic Alternatives in Personal Care
3. Variability in Raw-Silk Quality and Supply Constraints

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, fibroin captured 33.89% of the silk protein market, primarily in textile yarns and implantable scaffolds. Hydrolyzed silk peptide, projected to grow at a 7.78% compound annual growth rate (CAGR), benefits from its soluble formats that easily disperse in serums and beverages. Whole silk protein, valued for its high molecular integrity in protective coatings, sees modest volumes due to its cost. Sericin, previously discarded, now finds commercial use in anti-aging films, supported by licensing from DSM-Firmenich. Silk amino acids, penetrating deeper skin layers, secure a premium position in lineage-care products.

Recombinant technologies are redefining boundaries, allowing preset molecular weights in silico. AMSilk's 139.9-kilodalton (kDa) biomimetic variant offers cashmere-like softness, while Spiber's library caters to injection-moldable resins. Peptide adoption gains traction from a Korean trial, highlighting elevated natural killer (NK)-cell activity at a daily dose of 7.5 grams. Thus, the choice of protein type will increasingly hinge on functional performance over extraction methods.

In 2025, powders dominated with 58.02% of the volume, a testament to the established spray-dry infrastructure in China and India. While powders boast a multi-year shelf life and easy freight, they fall short on bioavailability compared to finer particles. Nano-formulations, projected to grow at an 8.02% CAGR, benefit from precision electrospinning, producing fibers below 100 nanometers (nm) that expedite wound closure. Liquids, favored in private-label original equipment manufacturer (OEM) channels for their batching simplicity, face limitations in natural-label claims due to preservatives.

Despite electrospinning throughput rarely exceeding kilograms per hour, capping nano-form supply, the performance premium draws biomedical firms seeking targeted adhesion. While powders will remain a staple for bulk textiles, nano-forms are poised to dominate emerging medical and high-end cosmetic niches, indicating a bifurcated supply chain.

Geography Analysis

In 2025, Asia-Pacific accounted for a 41.03% market share and is projected to grow at an 8.32% compound annual growth rate (CAGR) through 2031. This growth is primarily driven by China, which represents 53% of the global raw silk market, and by India's modernization initiatives supported by federal funding. Countries such as Thailand, Japan, and South Korea are establishing fermentation plants, strengthening the region's supply chain for the biomedical and cosmetic industries. In North America, the transition from import reliance to domestic production is evident, with Canon Virginia's new production line set to launch in 2026, supported by state incentives. In Europe, regulatory frameworks play a significant role; for example, Evonik's facility in Slovakia produces several tons of spinning-grade powder monthly, meeting the demand of the local premium textile market.

North America's market share, though smaller, is increasing as brands prioritize onshore, animal-free supplies. Canon Virginia's new production line highlights this cross-sector interest. Additionally, academic spin-outs in California are achieving fermentation yields nearing 900 milligrams per liter (mg L-1). U.S. state subsidies aimed at rural job creation are positioning silk biotechnology as a key economic development driver. In Canada, pilot plants in Ontario are combining corn-based feedstocks with green hydroelectricity to produce zero-carbon silk inputs.

Europe is balancing stringent environmental regulations with its industrial capabilities. The European Union's (EU) microplastic ban is driving demand for biodegradable film-formers, and Evonik's Slovak facility is addressing this need by supplying regional cosmetics manufacturers through long-term tolling agreements. France's Ajinomoto fermentation hub, equipped with 100 cubic meter (m3) reactors, integrates Asian expertise into the European market. Additionally, Eastern European governments are offering tax holidays for biotech parks to attract further investments.

South America and the Middle East face challenges such as limited mulberry cultivation and insufficient capital for bioreactors. However, Asia-Pacific's combination of cocoon farming and industrial fermentation positions it for sustained growth, surpassing other regions. Protectionist sourcing regulations, however, may lead to redundant capacity in Western markets.

1. AMSilk GmbH
2. Bolt Threads Inc.
3. Croda International Plc
4. dsm-firmenich
5. Evolved By Nature Inc.
6. Evonik Industries AG
7. Givaudan
8. Huzhou Aotesi Biochemical
9. JRS Pharma
10. LANXESS
11. Lonza
12. MATEXCEL
13. PlanAdv S.r.l.s.
14. SEIWA KASEI Co., Ltd.
15. Spiber Inc.
16. Suzhou Suhao BioTech
17. Wuxi Boton Technology
18. Zhejiang Jiaxin Silk Corp., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing demand for natural and functional ingredients in cosmetics
  • 4.2.2 Surging biomedical use (wound dressings, drug delivery)
  • 4.2.3 Rising interest in sustainable and biodegradable textiles
  • 4.2.4 Regulatory push for micro-plastic alternatives in personal-care
  • 4.2.5 Breakthroughs in recombinant / microbial silk-protein production
  • 4.2.6 Expansion of plant-based recombinant silk platforms lowering CAPEX
• 4.3 Market Restraints
  • 4.3.1 High extraction and purification costs
  • 4.3.2 Variability in raw-silk quality and supply constraints
  • 4.3.3 Allergenicity and regulatory uncertainty for ingestible silk peptides
  • 4.3.4 Limited scalability of sericulture outside Asia-Pacific
• 4.4 Value Chain Analysis
• 4.5 Porter's Five Forces
  • 4.5.1 Bargaining Power of Suppliers
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Threat of New Entrants
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Protein Type
  • 5.1.1 Fibroin
  • 5.1.2 Sericin
  • 5.1.3 Whole Silk Protein
  • 5.1.4 Hydrolyzed Silk Peptide
  • 5.1.5 Silk Amino Acids
• 5.2 By Form
  • 5.2.1 Powder
  • 5.2.2 Liquid
  • 5.2.3 Nano-formulation
• 5.3 By Application
  • 5.3.1 Personal Care and Cosmetics
  • 5.3.2 Biomedical and Pharmaceutical
  • 5.3.3 Textiles and Fabrics
  • 5.3.4 Food and Dietary Supplements
  • 5.3.5 Coatings and Adhesives
• 5.4 By End-user Industry
  • 5.4.1 Cosmetics & Personal-Care Manufacturers
  • 5.4.2 Healthcare & Medical-Device Companies
  • 5.4.3 Textile & Apparel Companies
  • 5.4.4 Food & Nutrition Companies
  • 5.4.5 Other Industrial Users (Packaging, Coatings)
• 5.5 By Geography
  • 5.5.1 Asia-Pacific
    • 5.5.1.1 China
    • 5.5.1.2 Japan
    • 5.5.1.3 India
    • 5.5.1.4 South Korea
    • 5.5.1.5 ASEAN Countries
    • 5.5.1.6 Rest of Asia-Pacific
  • 5.5.2 North America
    • 5.5.2.1 United States
    • 5.5.2.2 Canada
    • 5.5.2.3 Mexico
  • 5.5.3 Europe
    • 5.5.3.1 Germany
    • 5.5.3.2 United Kingdom
    • 5.5.3.3 France
    • 5.5.3.4 Italy
    • 5.5.3.5 Spain
    • 5.5.3.6 Russia
    • 5.5.3.7 Rest of Europe
  • 5.5.4 South America
    • 5.5.4.1 Brazil
    • 5.5.4.2 Argentina
    • 5.5.4.3 Rest of South America
  • 5.5.5 Middle East and Africa
    • 5.5.5.1 Saudi Arabia
    • 5.5.5.2 South Africa
    • 5.5.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.4.1 AMSilk GmbH
  • 6.4.2 Bolt Threads Inc.
  • 6.4.3 Croda International Plc
  • 6.4.4 dsm-firmenich
  • 6.4.5 Evolved By Nature Inc.
  • 6.4.6 Evonik Industries AG
  • 6.4.7 Givaudan
  • 6.4.8 Huzhou Aotesi Biochemical
  • 6.4.9 JRS Pharma
  • 6.4.10 LANXESS
  • 6.4.11 Lonza
  • 6.4.12 MATEXCEL
  • 6.4.13 PlanAdv S.r.l.s.
  • 6.4.14 SEIWA KASEI Co., Ltd.
  • 6.4.15 Spiber Inc.
  • 6.4.16 Suzhou Suhao BioTech
  • 6.4.17 Wuxi Boton Technology
  • 6.4.18 Zhejiang Jiaxin Silk Corp., Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment